This cohort study compares Medicare Advantage beneficiaries and traditional Medicare beneficiaries newly diagnosed with cancer with regards to timeliness of initial treatment, receiving the optimum in...

The Medicare prescription drug plan redesign under the Inflation Reduction Act of 2022 aims to simplify the Part D benefit while capping out-of-pocket spending for Part D–covered drugs. Whether and wh...

PURPOSEPeople experiencing housing insecurity (PEHI) may face barriers to preventive cancer screening, but the extent to which PEHI receive screening at the population level is understudied. Therefore...

A spokesperson for the University told WESA Friday that the school has "temporarily paused additional Ph.D. offers of admission," while Pitt works to understand how proposed federal funding cuts could...

This cohort study examines the current patterns of end-of-life care among older, fee-for-service Medicare decedents with advanced cancer.

Our latest survey finds that 86% of those receiving enhanced premium tax credits would have difficulty getting care if the credits expire at the end of 2025, and very few (25%) are aware of the enhanc...

This explainer discusses the value of Medicaid to its many beneficiaries.

An obscure health insurance alternative is seeing tremendous growth. But there’s a catch.

In 2025, Medicare beneficiaries will pay no more than $2,000 out of pocket for prescription drugs covered under Part D, Medicare’s outpatient drug benefit, due to a provision in the Inflation Reductio...